Gene therapy

Biotech Jason Mast

STAT Plus: Ultragenyx gene therapy for rare liver ailment succeeds in late-stage trial

Biotech Timmy Broderick

STAT Plus: Gene therapies for deafness dredge up an old question: Do deaf people want a ‘cure’?

Biotech Jason Mast

STAT Plus: Q&A with Jennifer Adair, researcher on a mission to increase global access to gene therapies

Biotech Timmy Broderick

STAT Plus: After gene therapy, two congenitally deaf children hear for the first time

Pharma Jason Mast

STAT Plus: Young boy dies in trial for Pfizer Duchenne gene therapy

Biotech Jason Mast

STAT Plus: Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chief

The Readout Elaine Chen

STAT Plus: Bernie Sanders targets ‘outrageously high price’ of Ozempic

Opinions+ Lee A. Fleisher and Matthew A. Fleisher

STAT Plus: Use evidence to support early coverage of gene therapy after accelerated approval

Biotech Jason Mast

STAT Plus: Why the world’s most expensive drug might not be all that overpriced

Biotech Allison DeAngelis and Mario Aguilar

STAT Plus: How biotech investors spot opportunity when stocks are down — and up

Biotech Jason Mast and Megan Molteni

STAT Plus: New gene therapy, to be priced at $4.25 million, has already transformed children’s lives

Biotech Jason Mast

STAT Plus: FDA approves first gene therapy for fatal neuron disease in children

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

A dilemma in ALS, the first MASH drug, & why gene therapy is hard

Biotech Jason Mast

STAT Plus: Hemophilia gene therapies arrived after 40 years of struggle. Where are the patients?

In the Lab Megan Molteni

Meet the fetal surgeon forging CRISPR’s next frontier: curing diseases in the womb

Biotech Jason Mast

STAT Plus: Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

In the Lab Andrew Joseph

STAT Plus: A gene therapy designed to heal skin wounds helped preserve a boy’s vision

Exclusive Megan Molteni

Texas Medicaid agrees to fully cover gene therapy for Afghan refugees’ infant

Adam's Take Adam Feuerstein

STAT Plus: Can gene therapies make for a profitable business? Keep your eye on Bluebird Bio

Biotech Adam Feuerstein

STAT Plus: FDA expands approval of CRISPR-based medicine to treat beta thalassemia

Health Megan Molteni

In partial reversal, Texas Medicaid greenlights first step in gene therapy for Afghan refugees’ infant son

Adam's Take Adam Feuerstein

STAT Plus: FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy

Biotech Jason Mast

STAT Plus: Doudna institute hatches plan to ‘cure hundreds of diseases’ left behind by CRISPR revolution

Exclusive Megan Molteni

STAT Plus: The Afghan father aided U.S. soldiers. Now Texas Medicaid won’t pay for his son’s gene therapy

Special Report Brittany Trang

STAT Plus: Gene therapy offered this 7-year-old freedom. The price: a grueling year

Biotech Jason Mast

STAT Plus: Could sickle cell someday be treated not with CRISPR, but with a pill?

Health Jonathan Wosen

STAT Plus: Bone marrow transplant advance could widen use of this less buzzy cure for sickle cell disease

First Opinion Robert Brodsky

New sickle cell disease CRISPR treatments can’t make up for the shortage of adult hematologists

Biotech Brittany Trang

STAT Plus: Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy